Quarterly report pursuant to Section 13 or 15(d)

Intangible Assets

v3.20.1
Intangible Assets
 6 Months Ended
Mar. 31, 2020
Intangible Assets  
Intangible Assets

 

8. Intangible Assets

The Company’s intangible assets consisted of the following:

 

 

 

 

 

 

 

 

 

 

 

March 31,

 

September 30,

 

Estimated useful

 

    

2020

    

2019

    

life (in months)

Clinical trial data

 

$

250,000

 

$

250,000

 

 6

Accumulated amortization

 

 

(250,000)

 

 

(104,167)

 

  

Intangible assets, net

 

$

 —

 

$

145,833

 

  

 

Amortization expense for the three months ended March 31,2020 and 2019 was approximately $0.02 million and $0, respectively. Amortization expense for the six months ended March 31,2020 and 2019 was approximately $0.15 million and $0, respectively.